A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells

Biochemical Pharmacology

Volumn 76, Issue 3, 2008, Pages 353-361

  Rockwell, Cheryl E ^a   Raman, Priyadarshini ^a   Kaplan, Barbara L F ^a   Kaminski, Norbert E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

2 AG; 2 AG ether; 2 Arachidonyl glycerol; Anandamide; Cannabinoid; COX; Cyclooxygenase; Endocannabinoid; IL 2; Jurkat; T cell

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; INTERLEUKIN 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACIDS; BLOTTING, WESTERN; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOCANNABINOIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCERIDES; HUMANS; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; SPLEEN;

EID: 46649101803     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.05.005     Document Type: Article

References (47)

1. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 1 (1995) 83-90
2. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256 2 (1999) 377-380
3. Maccarrone M., Falciglia K., Di Rienzo M., and Finazzi-Agro A. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids 66 2-3 (2002) 309-317
4. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65 4 (2004) 999-1007
5. Matias I., Pochard P., Orlando P., Salzet M., Pestel J., and Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269 15 (2002) 3771-3778
6. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264 1 (1999) 258-267
7. Witting A., Walter L., Wacker J., Moller T., and Stella N. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci USA 101 9 (2004) 3214-3219
8. Maccarrone M., Bari M., Battista N., and Finazzi-Agro A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 1 1 (2002) 53-63
9. Kishimoto S., Gokoh M., Oka S., Muramatsu M., Kajiwara T., Waku K., et al. 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278 27 (2003) 24469-24475
10. Lee M., Yang K.H., and Kaminski N.E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275 2 (1995) 529-536
11. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275 1 (2000) 605-612
12. Ouyang Y., Hwang S.G., Han S.H., and Kaminski N.E. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 53 4 (1998) 676-683
13. Kaplan B.L., Ouyang Y., Herring A., Yea S.S., Razdan R., and Kaminski N.E. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2′-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicol Appl Pharmacol 205 2 (2005) 107-115
14. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., and Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41 2 (2003) 161-168
15. Chang Y.H., Lee S.T., and Lin W.W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 81 4 (2001) 715-723
16. Goparaju S.K., Ueda N., Yamaguchi H., and Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422 1 (1998) 69-73
17. Goparaju S.K., Ueda N., Taniguchi K., and Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57 4 (1999) 417-423
18. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46 5 (1993) 791-796
19. Kozak K.R., Rowlinson S.W., and Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275 43 (2000) 33744-33749
20. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 52 (1996) 33157-33160
21. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
22. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277 47 (2002) 44877-44885
23. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 5 (1995) 813-819
24. Rockwell C.E., Snider N.T., Thompson J.T., Vanden Heuvel J.P., and Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70 1 (2006) 101-111
25. Faubert Kaplan B.L., and Kaminski N.E. Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. Int Immunopharmacol 3 10-11 (2003) 1503-1510
26. Farraj A.K., Harkema J.R., and Kaminski N.E. Allergic rhinitis induced by intranasal sensitization and challenge with trimellitic anhydride but not with dinitrochlorobenzene or oxazolone in A/J mice. Toxicol Sci 79 2 (2004) 315-325
27. Rockwell C.E., and Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 311 2 (2004) 683-690
28. Berg D.J., Zhang J., Lauricella D.M., and Moore S.A. Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol 166 4 (2001) 2674-2680
29. Ho W.S., and Randall M.D. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150 5 (2007) 641-651
30. O'Sullivan S.E., Kendall D.A., and Randall M.D. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur J Pharmacol 507 1-3 (2005) 211-221
31. Motobe T., Hashiguchi T., Uchimura T., Yamakuchi M., Taniguchi N., Komiya S., et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. Shock 21 1 (2004) 8-12
32. Hillard C.J., and Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140 5 (2003) 802-808
33. Beltramo M., and Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11 6 (2000) 1231-1235
34. Otto J.C., DeWitt D.L., and Smith W.L. N-Glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 268 24 (1993) 18234-18242
35. Wennogle L.P., Liang H., Quintavalla J.C., Bowen B.R., Wasvary J., Miller D.B., et al. Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett 371 3 (1995) 315-320
36. Kozak K.R., and Marnett L.J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66 2-3 (2002) 211-220
37. Moody J.S., Kozak K.R., Ji C., and Marnett L.J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40 4 (2001) 861-866
38. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 5 (1995) 803-812
39. Zhang X., and Young H.A. PPAR and immune system-what do we know?. Int Immunopharmacol 2 8 (2002) 1029-1044
40. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 23 3 (2002) 144-150
41. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 6662 (1998) 79-82
42. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 7 (2000) 4541-4544
43. Bell-Parikh L.C., Ide T., Lawson J.A., McNamara P., Reilly M., and FitzGerald G.A. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 112 6 (2003) 945-955
44. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270 41 (1995) 23975-23983
45. Kozak K.R., Gupta R.A., Moody J.S., Ji C., Boeglin W.E., DuBois R.N., et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277 26 (2002) 23278-23286
46. Schmid P.C., Paria B.C., Krebsbach R.J., Schmid H.H., and Dey S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 94 8 (1997) 4188-4192
47. Peroni R.N., Orliac M.L., Becu-Villalobos D., Huidobro-Toro J.P., Adler-Graschinsky E., and Celuch S.M. Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. Eur J Pharmacol 493 1-3 (2004) 151-160